Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 405 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
Patents for C07D 405 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom (69,397)
06/2005
06/02/2005WO2005049582A1 Method of preparation of novel nucleoside analogs and uses
06/02/2005WO2005049578A1 Substituted pyrazoles as ppar agonists
06/02/2005WO2005049577A1 1-amino-isoquinoline derivatives for the treatment of diseases associated with inappropriate alk5
06/02/2005WO2005049023A1 Glyt1 transporter inhibitors
06/02/2005WO2005048953A2 Amide derivatives as kinase modulators
06/02/2005WO2005048948A2 Urea derivatives as kinase modulators
06/02/2005WO2005048922A2 Sulfonylaminovalerolactams and derivatives thereof as factor xa inhibitors
06/02/2005WO2005027823A3 3-heterocyclyl-indole derivatives as inhibitors of glycogen synthase kinase-3 (gsk-3)
06/02/2005WO2005016879A3 Cyclic pyrazinoylguanidine sodium channel blockers
06/02/2005US20050119489 Antidiabetic, anorexigenic, hypotensive, and anticholesterol agents that are synergistically combined with other active agents; obesity, premenstrual tension, hyperlipidemia, myocardial infarction and skin disorders
06/02/2005US20050119484 Mitotic kinesin inhibitors
06/02/2005US20050119329 Tetronic and tetramic acids
06/02/2005US20050119318 Inhibitors of HCV replication
06/02/2005US20050119296 6-(1-benzofuran-2-yl)-2-(trifluoromethyl)quinolin-4-yl 1H-tetraazol-5-ylmethylether; plasminogen activator inhibitor; impairment of fibrinolytic system; cystic fibrosis, diabetes, chronic periodontitis, lymphomas; increased uPA levels (breast and ovarian cancer)
06/02/2005US20050119271 Pyrimidine A2B selective antagonist compounds, their synthesis and use
06/02/2005US20050119260 5-(7-Chloro-1-methyl-1H-indol-3-ylmethyl)-3-methyl-imidazolidine-2,4-dione; neurodegenerative and necrotic cell disease; non-apoptotic/caspase-independent cell death mechanisms; ischemia, stroke, cardiac infarction, infection and sepsis
06/02/2005US20050119255 Phenylpyrimidine amines as ige inhibitors
06/02/2005US20050119250 Amino-derivatives as novel inhibitors of histone deacetylase
06/02/2005US20050119231 Quinolone antibiotics such as 3-Amino-1-cyclopropyl-6-fluoro-7-(3-hydroxymethyl-pyrrolidin-1-yl)-8-methoxy-1H-quinazoline-2,4-dione, used for treating gramnegative or grampositive bacterial infection in mammals
06/02/2005US20050119225 Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs
06/02/2005DE10123573B4 N-Oxidanthranylamid-Derivate und deren Verwendung als Arzneimittel N-Oxidanthranylamid derivatives and their use as medicaments
06/02/2005CA2545711A1 Urea derivatives as kinase modulators
06/01/2005EP1535920A1 Process for preparation of 1,3-benzodioxole-2-spiro- cycloalkane derivatives
06/01/2005EP1535915A1 Furan or thiophene derivative and medicinal use thereof
06/01/2005EP1535914A1 Processes for producing epoxytriazole derivative and intermediate therefor
06/01/2005EP1535909A2 Cyclic amine derivatives and their use as drugs
06/01/2005EP1535906A1 Nitrogen-containing compounds
06/01/2005EP1534704A1 Process for preparing 5-(4-fluorophenyl)-1-[2-((2r,4r)-4-hydroxy -6-oxo-tetrahydro-pyran-2-yl)ethyl]-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide
06/01/2005EP1534703A2 Antagonists of melanin concentrating hormone receptor
06/01/2005EP1534695A2 Tyrosine kinase inhibitors
06/01/2005EP1534685A1 1h-indazole-3-carboxamide compounds as cyclin dependent kinases (cdk) inhibitors
06/01/2005EP1534681A1 Substituted quinoline ccr5 receptor antagonists
06/01/2005EP1534676A1 Piperidinetriol derivatives as inhibitors of glycosylceramide synthase
06/01/2005EP1534391A1 Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders
06/01/2005EP1534292A2 Protease inhibitors
06/01/2005EP1534277A1 Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
06/01/2005EP1534276A2 Non-nucleoside reverse transcriptase inhibitors
06/01/2005EP1534273A2 Modulators of the glucocorticoid receptor and method
06/01/2005EP1534268A2 Tyrosine kinase inhibitors
06/01/2005EP1534264A2 Compounds that modulate the activity of ptp-1b and tc-ptp
06/01/2005EP1534255A2 Processes for preparing 1,3-dioxolane nucleosides
06/01/2005EP1404330B1 Substituted 8-arylquinoline pde4 inhibitors
06/01/2005EP1268465B1 Triarylimidazole derivatives as cytokine inhibitors
06/01/2005EP1188754B1 Substituted pyrazole compounds
06/01/2005EP1114030B1 Pyridine ketones useful as herbicides
06/01/2005EP1062210B1 1,2-diazepane derivatives as interleukin-1beta converting enzyme inhibitors
06/01/2005EP1009758B1 Meta-benzamidine derivatives as serine protease inhibitors
06/01/2005EP0708756B1 Substituted 2-phenylpyridines with herbicidal action
06/01/2005CN1622944A Method for producing 2-[-5-(4-fluoprophenyl)-3-pyridylmethylaminomethyl]-chromane
06/01/2005CN1622942A HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
06/01/2005CN1622937A Process for the manufacture of HMG-coa reductase inhibitors
06/01/2005CN1622807A Phenylpyrimidine amines as IgE inhibitors
06/01/2005CN1204135C 1, 3-dioxolanes with antitussive activity
06/01/2005CN1204134C Sulfamine-substituted benzodihydopyran, preparation method, use as medicine or diagnostic reagent and medicine containing same
06/01/2005CN1204121C 1, 4-substituted cyclic amine derivatives or dihydro indole derivatives and medicines containing same
06/01/2005CN1203899C Compounds with chelation affinity and selectivity for first transition series elements, and their use in medical therapy
05/2005
05/31/2005US6900336 8-aza-11-deoxy prostaglandin analogues
05/31/2005US6900329 MCH antagonists and their use in the treatment of obesity
05/31/2005US6900328 Stabilizer for polymers; photostability, oxidation resistance
05/31/2005US6900327 Used as antidepressants, to treat obsessive compulsive disorder, panic disorders, bulimia, anorexia, pain, obesity, senile demential, migraines, and social phobias
05/31/2005US6900301 Oligonucleotides for use in human therapeutics an diagnostics
05/31/2005US6900232 For therapy of tumor metastasis, solid tumor growth (neoplasia), osteoporosis, Paget's disease, humoral hypercalcemia of malignancy, osteopenia, angiogenesis, including tumor angiogenesis and lymphangiogenesis
05/31/2005US6900230 Heterocyclo-alkylsulfonyl pyrazoles as anti-inflammatory/analgesic agents
05/31/2005US6900227 Benzodioxole derivatives
05/31/2005US6900222 Relaxant drugs; antiulcer agents
05/31/2005US6900220 Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists
05/31/2005US6900218 Reducing oxidation stresses; central nervous system disorders; antiinflammatory agents
05/31/2005US6900214 Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
05/31/2005US6900212 Anxiolytic agents; psychological disorders; sexual disorders; eating disorders
05/31/2005US6900210 Pyridinyl, pyrimidinyl and pyrazinyl amides as potassium channel openers
05/31/2005US6900196 Serine protease inhibitors
05/31/2005US6900194 Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors for the treatment of respiratory diseases
05/31/2005US6900161 Azole or triazole derivatives, method for preparing same and use thereof as fungicides
05/26/2005WO2005047906A1 Methods for monitoring il-18
05/26/2005WO2005047899A2 Use of the lipoxin receptor, fprl1, as a tool for identifying compounds effective in the treatment of pain and inflammation
05/26/2005WO2005047266A1 Aryl imidazoles and their use as anti-cancer agents
05/26/2005WO2005047257A2 Methods and compositions for selectin inhibition
05/26/2005WO2005047255A1 Substituted nicotinoylcarbamates as pesticides
05/26/2005WO2005047251A1 Melanocortin receptor agonists
05/26/2005WO2005047250A1 N-acylated-3- (benzoyl) - pyrrolidines as 11-beta-hsd1 inhibitors useful for the treatment of metabolic disorders.
05/26/2005WO2005047249A1 Benzylether amine compounds useful as ccr-5 antagonists
05/26/2005WO2005047248A1 4-biarylyl-1-phenylazetidin-2-ones
05/26/2005WO2005047244A2 Inhibition of fgfr3 and treatment of multiple myeloma
05/26/2005WO2005046698A1 Fused heterocyclic compounds
05/26/2005WO2005046688A2 Methods of use of thrombin receptor antagonists
05/26/2005WO2005046685A1 Substituted piperidines for the treatment of metabolic syndrome
05/26/2005WO2005046683A1 Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
05/26/2005WO2005046679A1 Immuno inhibitory pyrazolone compounds
05/26/2005WO2005046604A2 Heteroaryl-hydrazone compounds
05/26/2005WO2005046603A2 Pyridine compounds
05/26/2005WO2005046590A2 Methods for synthesizing quinolinone compounds
05/26/2005WO2005046589A2 Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties
05/26/2005WO2005046578A2 Isoquinolinone potassium channel inhibitors
05/26/2005WO2005019168A8 Fluorinated lysine derivatives as dipeptidyl peptidase iv inhibitors
05/26/2005WO2004112719A8 Chemical compounds
05/26/2005WO2004111000A3 Piperidyl derivatives and their use as tachykinin antagonists
05/26/2005WO2004078851B1 Novel dyes and use thereof in thermal imaging members and methods
05/26/2005US20050113583 Process for preparing glycidylphthalimide
05/26/2005US20050113578 Process for preparing substituted pyridines
05/26/2005US20050113566 Inhibitors of C-FMS kinase
1 ... 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 ... 694